Department of Cell and Developmental Biology

Craig Brooks, PhD, and colleagues are studying a molecular mechanism that promotes chronic kidney disease following kidney injury. (photo by Erin O. Smith)

Novel therapeutic target identified for chronic kidney disease

Vanderbilt investigators have discovered a molecular mechanism that promotes chronic kidney disease following kidney injury.

Highly multiplexed, untargeted MALDI imaging mass spectrometry data reveal the localization of various lipids and metabolites to specific functional regions of the nephron, the kidney's filtering unit (right).

Grants spur efforts to create molecular ‘atlases’ of organs

Vanderbilt researchers have received three grants totaling $13.6 million from the National Institutes of Health to develop molecular “atlases” of the brain, kidney, eye and other tissues.

Colon cancer researchers awarded NCI grant for study of early lesions

Vanderbilt researchers are studying precancerous lesions and early cancers in the colon, with the goal of developing new ways to prevent colorectal cancer, the nation’s second leading cancer killer.

C. difficile may contribute to colorectal cancer: study

A Vanderbilt study found that the bacterium Clostridioides difficile (C. difficile) may be a previously unrecognized contributor to colorectal cancer.

Anna Means, PhD, R. Daniel Beauchamp, MD, and colleagues are studying a group of proteins that are essential to the growth of colorectal cancer tumors.

Researchers find potential new target against colorectal cancer

The study team included (front row, from left) Kelsey Voss, PhD, Rachel Bonami, PhD, Erin Wilfong, MD, PhD, (back row, from left) Jonathan Irish, PhD, Jeff Rathmell, PhD, and Ivelin Georgiev, PhD.

Vanderbilt team tracks cellular and antibody responses to COVID-19 vaccine

In a technical tour de force, a collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine.

1 2 3 4 13